Breaking: Mizuho Securities Reiterates $9.0000 PT On Depomed (NASDAQ:DEPO) Shares, Reiterates Their Original Buy Rating

May 17, 2018 - By Duane Lopez

Depomed, Inc. (NASDAQ:DEPO) Logo

Investors sentiment decreased to 0.93 in Q4 2017. Its down 0.28, from 1.21 in 2017Q3. It worsened, as 28 investors sold Depomed, Inc. shares while 47 reduced holdings. 24 funds opened positions while 46 raised stakes. 55.87 million shares or 0.97% less from 56.42 million shares in 2017Q3 were reported.

Art Advisors Ltd Limited Liability Company stated it has 60,374 shares or 0.02% of all its holdings. State Teachers Retirement System invested 0% in Depomed, Inc. (NASDAQ:DEPO). Voya Inv Mgmt Limited Liability holds 0% or 27,068 shares. State Board Of Administration Of Florida Retirement System owns 0% invested in Depomed, Inc. (NASDAQ:DEPO) for 100,902 shares. Tsp Mngmt Grp Lc reported 53,025 shares or 0.19% of all its holdings. 730,783 were accumulated by Financial Bank Of New York Mellon. Goldman Sachs Group has 0% invested in Depomed, Inc. (NASDAQ:DEPO). Vanguard Grp Inc Incorporated Inc holds 0% or 4.15 million shares. Thrivent Finance For Lutherans invested in 39,366 shares. Pacad Invest Limited has 36,300 shares. Prudential Fincl Inc reported 102,116 shares. Manufacturers Life Ins Co The has invested 0% in Depomed, Inc. (NASDAQ:DEPO). Sei Investments Comm has 0% invested in Depomed, Inc. (NASDAQ:DEPO). Texas Permanent School Fund accumulated 0% or 42,560 shares. Royal Natl Bank Of Canada holds 0% of its portfolio in Depomed, Inc. (NASDAQ:DEPO) for 2,504 shares.

Since December 14, 2017, it had 1 insider purchase, and 2 sales for $173,390 activity. 75,000 shares were bought by HIGGINS ARTHUR J, worth $612,000 on Thursday, December 14.

Depomed (NASDAQ:DEPO) Rating Reaffirmed

Mizuho Securities now has a $9.0000 target on the $481.45M market cap company or 18.73 % upside potential. In a note issued to investors and clients on Wednesday, 16 May, Depomed (NASDAQ:DEPO) shares have had their Buy Rating reiterated by research analysts at Mizuho Securities.

Depomed, Inc. (NASDAQ:DEPO) Ratings Coverage

Among 4 analysts covering Depomed Inc (NASDAQ:DEPO), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Depomed Inc has $10.0 highest and $900 lowest target. $9.25’s average target is 22.03% above currents $7.58 stock price. Depomed Inc had 6 analyst reports since December 5, 2017 according to SRatingsIntel. Mizuho maintained Depomed, Inc. (NASDAQ:DEPO) rating on Friday, March 23. Mizuho has “Buy” rating and $900 target. The stock of Depomed, Inc. (NASDAQ:DEPO) has “Buy” rating given on Friday, March 2 by Roth Capital. The stock of Depomed, Inc. (NASDAQ:DEPO) earned “Buy” rating by Mizuho on Thursday, May 10. As per Tuesday, December 5, the company rating was maintained by Piper Jaffray. As per Wednesday, December 6, the company rating was maintained by RBC Capital Markets. The firm earned “Buy” rating on Tuesday, December 5 by Mizuho.

The stock increased 0.80% or $0.06 during the last trading session, reaching $7.58. About 977,631 shares traded. Depomed, Inc. (NASDAQ:DEPO) has declined 57.25% since May 18, 2017 and is downtrending. It has underperformed by 68.80% the S&P500.

Analysts await Depomed, Inc. (NASDAQ:DEPO) to report earnings on August, 6. They expect $-0.30 EPS, up 30.23 % or $0.13 from last year’s $-0.43 per share. After $0.48 actual EPS reported by Depomed, Inc. for the previous quarter, Wall Street now forecasts -162.50 % negative EPS growth.

Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. The company has market cap of $481.45 million. It offers Gralise , an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. It currently has negative earnings. The firm also provides NUCYNTA ER (tapentadol extended release tablets), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA (tapentadol), a product for the management of moderate to severe acute pain in adults.

More notable recent Depomed, Inc. (NASDAQ:DEPO) news were published by: Globenewswire.com which released: “Depomed Announces First-Quarter 2018 Financial Results” on May 10, 2018, also Seekingalpha.com with their article: “Depomed Earnings Preview” published on May 09, 2018, Seekingalpha.com published: “Depomed Inc. 2018 Q1 – Results – Earnings Call Slides” on May 10, 2018. More interesting news about Depomed, Inc. (NASDAQ:DEPO) were released by: Globenewswire.com and their article: “Depomed to Present at the UBS Global Healthcare Conference” published on May 05, 2018 as well as Seekingalpha.com‘s news article titled: “FDA OKs first non-opioid treatment for opioid withdrawal” with publication date: May 16, 2018.

Depomed, Inc. (NASDAQ:DEPO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: